Application of MAPRE3 as a diagnostic marker for sunitinib resistance in renal cell carcinoma
By using MAPRE3 as a diagnostic marker for sunitinib resistance in renal cell carcinoma, detecting MAPRE3 expression and developing corresponding inhibitors, the challenges of predicting and treating sunitinib resistance in renal cell carcinoma have been solved, enabling individualized treatment and reversal of drug resistance in renal cell carcinoma patients.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- CENT HOSPITAL XUHUI DISTRICT SHANGHAI CITY
- Filing Date
- 2026-06-15
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies lack effective biomarkers to predict sunitinib resistance in renal cell carcinoma, and there are no methods to reverse or delay resistance, which makes renal cell carcinoma patients prone to developing resistance and metastasis after using sunitinib.
Using MAPRE3, a member of the microtubule-associated protein RP/EB family, as a diagnostic biomarker for sunitinib resistance in renal cell carcinoma, we will provide kits for detecting and predicting drug resistance by detecting MAPRE3 expression levels, and develop MAPRE3 inhibitors to downregulate or block MAPRE3 protein to prepare anti-renal cell carcinoma drug resistance.
It can effectively predict and reverse sunitinib resistance in renal cell carcinoma, improve treatment efficacy, reduce recurrence, improve patient survival, provide individualized treatment plans, and avoid ineffective treatment and drug toxicity.
Smart Images
Figure CN122405818A_ABST